Cargando…

Heterologous regimen viral-vector/mRNA produces significantly higher SARS-CoV-2 humoral response than homologous viral-vector and inactivated vaccines in liver transplant recipients

Detalles Bibliográficos
Autores principales:	Mendizabal, Manuel, Ducasa, Nicolas, Benencio, Paula, Anders, Maria Margarita, Cairo, Fernando, Alter, Adriana, Etcheves, Patricia, Scarton, Giampaolo, Biglione, Mirna, Mauro, Ezequiel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association for the Study of the Liver. Published by Elsevier B.V. 2022
Materias:	POSTER PRESENTATIONS: Saturday 25 June: Liver transplantation and hepatobiliary surgery: Clinical aspects
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252413/ http://dx.doi.org/10.1016/S0168-8278(22)01883-9

Ejemplares similares

Heterologous adenovirus‐vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipients
por: Mendizabal, Manuel, et al.
Publicado: (2022)

Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients
por: Guarino, Maria, et al.
Publicado: (2022)

Sustainability of humoral immunity induced by the SARS-CoV-2 vaccine and response to booster dose among Liver Transplant recipients
por: Rabinowich, Liane, et al.
Publicado: (2022)

Durability of SARS-CoV-2 specific immune response following different primary prime-boost vaccine platforms and subsequent humoral response to booster dose among liver transplant recipients
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) specific cellular and humoral immunity in Corovavirus Disease-2019 (COVID-19) convalescence after liver transplantation-a prospective six month follow-up
por: Kirchner, Theresa, et al.
Publicado: (2022)

SARS-CoV-2 vaccination in liver transplant recipients: factors affecting immune response and refusal to vaccine
por: Raszeja-Wyszomirska, Joanna, et al.
Publicado: (2022)

The impact of COVID-19 on the duration of the liver transplant process in patients presenting for inpatient liver transplant evaluation
por: Cooper, Katherine, et al.
Publicado: (2022)

Impact of COVID-19 on the liver transplant activity in the US: variation by the region, etiology, and cirrhosis complications
por: Singal, Ashwani, et al.
Publicado: (2022)

Long-lasting seropositivity after anti SARS-CoV-2 vaccination in pre liver transplant patients
por: Calleri, Alberto, et al.
Publicado: (2022)

SARS-CoV-2 infection in liver transplant recipients-a single center case series from Romania
por: Husar-Sburlan, Ioana-Alexandra, et al.
Publicado: (2022)

Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in liver transplant recipients
por: Herrán, Aitor Odriozola, et al.
Publicado: (2022)

Does m-RNA vaccination protect from Sars-Cov2 (asymptomatic) infection in liver transplant recipients?
por: Comandini, Ubaldo Visco, et al.
Publicado: (2022)

Predictive factors of antibody response after anti-SARS-CoV-2 vaccine in liver transplant recipients
por: Kounis, Ilias, et al.
Publicado: (2022)

Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Efficacy and safety of SARS-CoV-2 vaccination in liver transplant recipients
por: Meunier, Lucy, et al.
Publicado: (2022)

Third dose of SARS-COV2 mRNA-vaccine in liver transplant recipients: can it bridge the response gap?
por: Montalbano, Marzia, et al.
Publicado: (2022)

Liver transplant patients infection rate with SARS-CoV-2 is lower but depend upon the infection rate in the general population and have a better outcome
por: Cohen-Naftaly, Michal, et al.
Publicado: (2022)

Reply
por: Mendizabal, Manuel, et al.
Publicado: (2022)

Safety and effectiveness of vaccines agains SARS-COV-2 in patients with liver cancer. VacHep registry: response analysis 4 weeks after the second dose.
por: Sempere, Elena Diago, et al.
Publicado: (2022)

Identification of Novel and Noninvasive Biomarkers of Acute Cellular Rejection After Liver Transplantation by Protein Microarray
por: Okubo, Keita, et al.
Publicado: (2016)

The Kupffer Cell Number Affects the Outcome of Living Donor Liver Transplantation from Elderly Donors
por: Hidaka, Masaaki, et al.
Publicado: (2016)

Normothermic Machine Perfusion of Deceased Donor Liver Grafts Is Associated With Improved Postreperfusion Hemodynamics
por: Angelico, Roberta, et al.
Publicado: (2016)

Reluctance to Accept Alcohol Treatment by Alcoholic Liver Disease Transplant Patients: A Qualitative Study
por: Heyes, Cathy M., et al.
Publicado: (2016)

Liberation From Renal Replacement Therapy After Cadaveric Liver Transplantation
por: Hilmi, Ibtesam A., et al.
Publicado: (2016)

Ethylene Glycol Poisoning Should Not Contraindicate Liver Donation
por: Burman, Alisha, et al.
Publicado: (2017)

Avoiding ICU Admission by Using a Fast-Track Protocol Is Safe in Selected Adult-to-Adult Live Donor Liver Transplant Recipients
por: Echeverri, Juan, et al.
Publicado: (2017)

Adapting the Surgical Apgar Score for Perioperative Outcome Prediction in Liver Transplantation: A Retrospective Study
por: Pearson, Amy C. S., et al.
Publicado: (2017)

Liver Transplantation From Donors With a History of Malignancy: A Single-Center Experience
por: Benkö, Tamas, et al.
Publicado: (2017)

Long-term Prognosis and Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation: A Single-Center Experience
por: Ueda, Yoshihide, et al.
Publicado: (2017)

A Formula to Calculate Standard Liver Volume Using Thoracoabdominal Circumference
por: Shaw, Brian I., et al.
Publicado: (2017)

The Implications of the Shift Toward Donation After Circulatory Death in Australia
por: Reiling, Janske, et al.
Publicado: (2017)

Rituximab Induction to Prevent the Recurrence of PSC After Liver Transplantation—The Lessons Learned From ABO-Incompatible Living Donor Liver Transplantation
por: Yamada, Yohei, et al.
Publicado: (2018)

Transplantation of a Liver Allograft From a Hepatitis C Virus Seropositive Donor With Previous Sustained Virologic Response to an Uninfected Recipient Suffering Steroid Refractory Acute Graft Rejection With No Evidence of HCV Transmission
por: Mitchell, Robert A., et al.
Publicado: (2018)

Cardiac MRI T2* in Liver Transplant Candidates: Application and Performance of a Novel Imaging Technique to Identify Patients at Risk for Poor Posttransplant Cardiac Outcomes
por: Lewin, Sara M., et al.
Publicado: (2018)

Liver Allograft Failure After Nivolumab Treatment—A Case Report With Systematic Literature Research
por: Gassmann, Dimitri, et al.
Publicado: (2018)

Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver Recipients
por: Engels, Eric A., et al.
Publicado: (2018)

The Impact of Implantation Time During Liver Transplantation on Outcome: A Eurotransplant Cohort Study
por: Jochmans, Ina, et al.
Publicado: (2018)

Accessory Gallbladder Complicating Liver Transplantation
por: Kesseli, Samuel J., et al.
Publicado: (2018)

Role of MRCP in Diagnosing Biliary Anastomotic Strictures After Liver Transplantation: A Single Tertiary Care Center Experience
por: Akbar, Ali, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ued3pglu830ev1e18n0fvnrk8m